Pyrukynd to treat hemolytic anemia
Drug Approval Name: Pyrukynd Indications: To treat hemolytic anemia in pyruvate kinase deficiency. Active Ingredient: Mitapivat Company: Agios Pharmaceuticals Inc Approval Date: 2/17/2022 Learn more: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-pyrukynd